Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan.
Kogetsu A, Isono M, Aikyo T, Furuta J, Goto D, Hamakawa N, Hide M, Hori R, Ikeda N, Inoi K, Kawagoe N, Kubota T, Manabe S, Matsumura Y, Matsuyama K, Nakai T, Nakao I, Saito Y, Senoo M, Takahashi MP, Takeda T, Takei M, Tamai K, Tanaka A, Torashima Y, Tsuchida Y, Yamasaki C, Yamamoto BA, Kato K. Kogetsu A, et al. Among authors: torashima y. Res Involv Engagem. 2023 Nov 29;9(1):107. doi: 10.1186/s40900-023-00515-5. Res Involv Engagem. 2023. PMID: 38031179 Free PMC article.
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, Yoshimoto T, Migita K, Kawaguchi Y, Kuba S, Morita M, Okada S, Kosaka T, Yamaguchi S, Inoue Y, Adachi T, Hidaka M, Torashima Y, Ito S, Takatsuki M, Eguchi S. Kobayashi K, et al. Among authors: torashima y. J Gastrointest Cancer. 2021 Jun;52(2):582-592. doi: 10.1007/s12029-020-00431-x. J Gastrointest Cancer. 2021. PMID: 32524305
S-1 and CPT-11 Plus Ramucirumab (IRIS+Rmab) as Second-Line Chemotherapy for Patients with Oxaliplatin-Refractory Metastatic Colorectal Cancer (mCRC): A Multicenter Phase II Study in Japan (N-DOCC-F-C-1701).
Kobayashi K, Morita M, Fukui S, Ito S, Inoue Y, Yamaguchi I, Mine Y, Kosaka T, Kuba S, Sakimura C, Yamanouchi K, Soyama A, Ono S, Adachi T, Natsuda K, Okada S, Tetsuo H, Ikebe A, Yamaguchi S, Enjoji T, Okada K, Haraguchi M, Taniguchi K, Fujioka H, Kuroki T, Matsuo M, Azuma T, Kamohara Y, Hashimoto T, Moriuchi H, Kitajima T, Kawakami S, Enjoji A, Suto R, Hidaka M, Torashima Y, Hayashida N, Kanetaka K, Takatsuki M, Eguchi S. Kobayashi K, et al. Among authors: torashima y. Kurume Med J. 2020 Jul 1;66(1):43-47. doi: 10.2739/kurumemedj.MS661007. Epub 2020 May 1. Kurume Med J. 2020. PMID: 32378536 Free article.
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Kobayashi K, Yamaguchi S, Ito S, Torashima Y, Inoue Y, Okada S, Enjoji T, Tetsuo H, Kuba S, Kosaka T, Adachi T, Hidaka M, Yamanouchi K, Kanetaka K, Takatsuki M, Eguchi S. Kobayashi K, et al. Among authors: torashima y. Intern Med. 2020 May 15;59(10):1239-1245. doi: 10.2169/internalmedicine.3274-19. Epub 2020 Feb 19. Intern Med. 2020. PMID: 32074573 Free PMC article.
29 results